AAPL299.11+2.10 (+0.71%) ▲|ABBV233.60+3.59 (+1.56%) ▲|ABT90.22+2.39 (+2.72%) ▲|ACN126.88+2.05 (+1.64%) ▲|ADBE197.77+2.87 (+1.47%) ▲|AMAT580.99-59.19 (-9.25%) ▼|AMD517.30-34.33 (-6.22%) ▼|AMGN347.52+2.80 (+0.81%) ▲|AMT178.51+2.08 (+1.18%) ▲|AMZN234.74+1.95 (+0.84%) ▲|AVGO380.92-11.22 (-2.86%) ▼|AXP337.37-0.71 (-0.21%) ▼|BA218.33-2.50 (-1.13%) ▼|BAC57.89+0.52 (+0.90%) ▲|BKNG168.67+0.90 (+0.53%) ▲|BLK1,016.29-35.45 (-3.37%) ▼|BMY55.85+1.15 (+2.10%) ▲|BNY147.50+1.06 (+0.72%) ▲|BRK-B492.96+4.27 (+0.87%) ▲|C145.34-0.34 (-0.23%) ▼|CAT985.22-37.06 (-3.63%) ▼|CL91.42+2.75 (+3.10%) ▲|CMCSA23.01+0.69 (+3.09%) ▲|COF197.35-3.35 (-1.67%) ▼|COP109.70+0.00 (+0.00%) ▲|COST958.86+7.51 (+0.79%) ▲|CRM153.84+3.72 (+2.48%) ▲|CSCO121.00-0.53 (-0.44%) ▼|CVS101.40+0.10 (+0.10%) ▲|CVX175.77+0.71 (+0.40%) ▲|DE591.40-7.20 (-1.20%) ▼|DHR178.80+0.61 (+0.34%) ▲|DIS103.66+1.21 (+1.18%) ▲|DUK125.25+1.73 (+1.40%) ▲|EMR143.58-6.63 (-4.41%) ▼|FDX321.20-7.59 (-2.31%) ▼|GD349.01+5.65 (+1.64%) ▲|GE355.79+0.67 (+0.19%) ▲|GEV1,039.82-87.78 (-7.78%) ▼|GILD125.63+0.76 (+0.61%) ▲|GM79.20-1.23 (-1.53%) ▼|GOOG346.27-2.51 (-0.72%) ▼|GOOGL346.86-2.70 (-0.77%) ▼|GS1,098.32-8.06 (-0.73%) ▼|HD325.59-1.03 (-0.32%) ▼|HON221.91-6.20 (-2.72%) ▼|IBM263.24+11.02 (+4.37%) ▲|INTC132.52-8.42 (-5.97%) ▼|INTU258.39+0.62 (+0.24%) ▲|ISRG402.25-0.70 (-0.17%) ▼|JNJ238.44+7.15 (+3.09%) ▲|JPM334.36+2.88 (+0.87%) ▲|KO80.19+0.66 (+0.83%) ▲|LIN514.63-2.08 (-0.40%) ▼|LLY1,107.53+5.45 (+0.49%) ▲|LMT501.23+7.63 (+1.55%) ▲|LOW214.15-0.25 (-0.12%) ▼|LRCX370.23-39.31 (-9.60%) ▼|MA488.29+4.20 (+0.87%) ▲|MCD271.95+1.85 (+0.68%) ▲|MDLZ61.06+1.55 (+2.60%) ▲|MDT80.48+1.21 (+1.53%) ▲|META563.77-0.08 (-0.01%) ▼|MMM162.01-1.22 (-0.74%) ▼|MO71.42+1.91 (+2.75%) ▲|MRK119.16+3.68 (+3.18%) ▲|MS226.52-0.58 (-0.25%) ▼|MSFT372.72+5.38 (+1.46%) ▲|MU1,049.14-162.24 (-13.39%) ▼|NEE86.46+0.38 (+0.44%) ▲|NFLX73.06+0.18 (+0.25%) ▲|NKE42.71-0.49 (-1.12%) ▼|NOW96.45+3.44 (+3.70%) ▲|NVDA200.95-7.70 (-3.69%) ▼|ORCL166.06-9.01 (-5.15%) ▼|PEP142.02+1.31 (+0.93%) ▲|PFE24.90-0.19 (-0.74%) ▼|PG150.97+3.29 (+2.23%) ▲|PLTR116.97-2.53 (-2.12%) ▼|PM177.44+4.27 (+2.47%) ▲|QCOM203.28-18.63 (-8.39%) ▼|RTX185.40+3.57 (+1.96%) ▲|SBUX101.08+0.93 (+0.93%) ▲|SCHW92.85+0.82 (+0.89%) ▲|SO94.82+1.39 (+1.49%) ▲|SPG216.79+2.22 (+1.03%) ▲|T22.92+0.82 (+3.69%) ▲|TMO467.35+3.34 (+0.72%) ▲|TMUS184.49+4.43 (+2.46%) ▲|TSLA381.24-23.81 (-5.88%) ▼|TXN302.71-29.58 (-8.90%) ▼|UBER69.70-1.73 (-2.42%) ▼|UNH408.04+1.36 (+0.33%) ▲|UNP259.48-0.43 (-0.17%) ▼|UPS105.98-1.27 (-1.18%) ▼|USB59.94+1.26 (+2.15%) ▲|V328.67+2.07 (+0.63%) ▲|VZ46.77+1.41 (+3.10%) ▲|WFC84.09+0.25 (+0.29%) ▲|WMT119.54+2.36 (+2.01%) ▲|XOM139.93+1.46 (+1.05%) ▲|AAPL299.11+2.10 (+0.71%) ▲|ABBV233.60+3.59 (+1.56%) ▲|ABT90.22+2.39 (+2.72%) ▲|ACN126.88+2.05 (+1.64%) ▲|ADBE197.77+2.87 (+1.47%) ▲|AMAT580.99-59.19 (-9.25%) ▼|AMD517.30-34.33 (-6.22%) ▼|AMGN347.52+2.80 (+0.81%) ▲|AMT178.51+2.08 (+1.18%) ▲|AMZN234.74+1.95 (+0.84%) ▲|AVGO380.92-11.22 (-2.86%) ▼|AXP337.37-0.71 (-0.21%) ▼|BA218.33-2.50 (-1.13%) ▼|BAC57.89+0.52 (+0.90%) ▲|BKNG168.67+0.90 (+0.53%) ▲|BLK1,016.29-35.45 (-3.37%) ▼|BMY55.85+1.15 (+2.10%) ▲|BNY147.50+1.06 (+0.72%) ▲|BRK-B492.96+4.27 (+0.87%) ▲|C145.34-0.34 (-0.23%) ▼|CAT985.22-37.06 (-3.63%) ▼|CL91.42+2.75 (+3.10%) ▲|CMCSA23.01+0.69 (+3.09%) ▲|COF197.35-3.35 (-1.67%) ▼|COP109.70+0.00 (+0.00%) ▲|COST958.86+7.51 (+0.79%) ▲|CRM153.84+3.72 (+2.48%) ▲|CSCO121.00-0.53 (-0.44%) ▼|CVS101.40+0.10 (+0.10%) ▲|CVX175.77+0.71 (+0.40%) ▲|DE591.40-7.20 (-1.20%) ▼|DHR178.80+0.61 (+0.34%) ▲|DIS103.66+1.21 (+1.18%) ▲|DUK125.25+1.73 (+1.40%) ▲|EMR143.58-6.63 (-4.41%) ▼|FDX321.20-7.59 (-2.31%) ▼|GD349.01+5.65 (+1.64%) ▲|GE355.79+0.67 (+0.19%) ▲|GEV1,039.82-87.78 (-7.78%) ▼|GILD125.63+0.76 (+0.61%) ▲|GM79.20-1.23 (-1.53%) ▼|GOOG346.27-2.51 (-0.72%) ▼|GOOGL346.86-2.70 (-0.77%) ▼|GS1,098.32-8.06 (-0.73%) ▼|HD325.59-1.03 (-0.32%) ▼|HON221.91-6.20 (-2.72%) ▼|IBM263.24+11.02 (+4.37%) ▲|INTC132.52-8.42 (-5.97%) ▼|INTU258.39+0.62 (+0.24%) ▲|ISRG402.25-0.70 (-0.17%) ▼|JNJ238.44+7.15 (+3.09%) ▲|JPM334.36+2.88 (+0.87%) ▲|KO80.19+0.66 (+0.83%) ▲|LIN514.63-2.08 (-0.40%) ▼|LLY1,107.53+5.45 (+0.49%) ▲|LMT501.23+7.63 (+1.55%) ▲|LOW214.15-0.25 (-0.12%) ▼|LRCX370.23-39.31 (-9.60%) ▼|MA488.29+4.20 (+0.87%) ▲|MCD271.95+1.85 (+0.68%) ▲|MDLZ61.06+1.55 (+2.60%) ▲|MDT80.48+1.21 (+1.53%) ▲|META563.77-0.08 (-0.01%) ▼|MMM162.01-1.22 (-0.74%) ▼|MO71.42+1.91 (+2.75%) ▲|MRK119.16+3.68 (+3.18%) ▲|MS226.52-0.58 (-0.25%) ▼|MSFT372.72+5.38 (+1.46%) ▲|MU1,049.14-162.24 (-13.39%) ▼|NEE86.46+0.38 (+0.44%) ▲|NFLX73.06+0.18 (+0.25%) ▲|NKE42.71-0.49 (-1.12%) ▼|NOW96.45+3.44 (+3.70%) ▲|NVDA200.95-7.70 (-3.69%) ▼|ORCL166.06-9.01 (-5.15%) ▼|PEP142.02+1.31 (+0.93%) ▲|PFE24.90-0.19 (-0.74%) ▼|PG150.97+3.29 (+2.23%) ▲|PLTR116.97-2.53 (-2.12%) ▼|PM177.44+4.27 (+2.47%) ▲|QCOM203.28-18.63 (-8.39%) ▼|RTX185.40+3.57 (+1.96%) ▲|SBUX101.08+0.93 (+0.93%) ▲|SCHW92.85+0.82 (+0.89%) ▲|SO94.82+1.39 (+1.49%) ▲|SPG216.79+2.22 (+1.03%) ▲|T22.92+0.82 (+3.69%) ▲|TMO467.35+3.34 (+0.72%) ▲|TMUS184.49+4.43 (+2.46%) ▲|TSLA381.24-23.81 (-5.88%) ▼|TXN302.71-29.58 (-8.90%) ▼|UBER69.70-1.73 (-2.42%) ▼|UNH408.04+1.36 (+0.33%) ▲|UNP259.48-0.43 (-0.17%) ▼|UPS105.98-1.27 (-1.18%) ▼|USB59.94+1.26 (+2.15%) ▲|V328.67+2.07 (+0.63%) ▲|VZ46.77+1.41 (+3.10%) ▲|WFC84.09+0.25 (+0.29%) ▲|WMT119.54+2.36 (+2.01%) ▲|XOM139.93+1.46 (+1.05%) ▲|
20.6 C
New York
Tuesday, June 23, 2026

Tag: FDA

newssourceFORcompanyinformationcontent1marketreleases

Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight

The interleukin-17 inhibitors market is expected to remain strong in rheumatology (psoriasis and arthritis), with potential expansion into hidradenitis suppurativa and other dermatologic conditions....

CVRx to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call on August 4, 2025

MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter 2025 financial and operating results after market close on Monday, August 4, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.

A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1-800-445-7795 for U.S. callers, or 1-785-424-1699 for international callers, approximately ten minutes prior to the start time. Please reference the following conference ID to access the call: CVRXQ225.

About CVRx, Inc.

CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com

Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, July 21, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to six (6) new employees to purchase 34,200 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee’s respective start date and 25% vesting on the second, third, and fourth anniversary thereafter. The options are subject to the terms and conditions of Avadel’s 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants.

UPDATE – Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference – The Sildenafil Cream That Raises the Bar

A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most

Medtronic secures CE Mark for MiniMed™ 780G System for insulin-requiring people with diabetes including expanded indications in children as young as two, during pregnancy,...

GALWAY, Ireland, July 21, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in medical technology, today announced CE (Conformité Européenne) Mark in...

CLL Society Awards Research Projects Advancing CLL/SLL Care

2025 Research Program supports innovative studies aimed at improving outcomes and quality of life for CLL and SLL patients SAN DIEGO, July 21, 2025 /PRNewswire/...

Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results

– Results Reflect Continued Financial Strength and Deleveraging –

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias

AUSTIN, Texas, July 21, 2025 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first...

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias

AUSTIN, Texas, July 21, 2025 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first...

CorestemChemon Expands Global CRO Reach with ATG Lifetech, Targeting Next-Gen Preclinical Services

Strategic partnership to deliver transcriptomics-powered, organoid-based preclinical testing for high-impact drug discovery  SEOUL, South Korea, July 20, 2025 /PRNewswire/ -- CorestemChemon, a leading GLP-certified preclinical...

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias

AUSTIN, Texas, July 21, 2025 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first...

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims & Hers (HIMS) or Sarepta (SRPT) To Contact Him Directly To Discuss Their Options

ThinkCareBelieve: Week 26 in America’s Rebirth under President Trump’s Leadership

Washington, DC, July 19, 2025 (GLOBE NEWSWIRE) --

Link to ThinkCareBelieve's Article:  https://thinkcarebelieve.blog/2025/07/19/week-26-in-americas-rebirth/

The Pink Salt Trick Recipe for Fast Weight Loss Trend in 2025: Why ProZenith Is the Science-Backed Alternative

Explore the Science Behind ProZenith’s Non-Stimulant Metabolic Support 
Explore the Science Behind ProZenith’s Non-Stimulant Metabolic Support

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsFDA

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers